Solventum Corporation (NYSE:SOLV) Given Average Recommendation of “Hold” by Analysts

Solventum Corporation (NYSE:SOLV) has received a consensus recommendation of “Hold” from the fourteen ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $90.8333.

A number of research analysts recently commented on the company. Stifel Nicolaus increased their price target on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Zacks Research cut Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. UBS Group restated a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. KeyCorp upgraded shares of Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 price objective on the stock in a research note on Monday, January 26th. Finally, Piper Sandler reissued an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th.

Institutional Investors Weigh In On Solventum

Institutional investors have recently made changes to their positions in the company. FORA Capital LLC bought a new position in Solventum during the fourth quarter worth $1,647,000. Kestra Advisory Services LLC lifted its position in shares of Solventum by 19.3% in the 4th quarter. Kestra Advisory Services LLC now owns 8,979 shares of the company’s stock worth $712,000 after buying an additional 1,454 shares during the last quarter. CreativeOne Wealth LLC acquired a new position in shares of Solventum in the 4th quarter valued at about $296,000. Marshall Wace LLP grew its position in shares of Solventum by 1.8% during the 4th quarter. Marshall Wace LLP now owns 160,529 shares of the company’s stock valued at $12,720,000 after buying an additional 2,860 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Solventum by 4.3% during the fourth quarter. The Manufacturers Life Insurance Company now owns 111,351 shares of the company’s stock worth $8,823,000 after acquiring an additional 4,585 shares during the period.

Solventum Stock Performance

Shares of SOLV stock opened at $75.59 on Friday. The company’s fifty day moving average price is $80.01 and its two-hundred day moving average price is $76.08. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The firm has a market capitalization of $13.11 billion, a P/E ratio of 8.71, a P/E/G ratio of 6.97 and a beta of 0.35. Solventum has a 12 month low of $60.70 and a 12 month high of $88.20.

Solventum announced that its Board of Directors has authorized a stock buyback plan on Thursday, November 20th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to repurchase up to 7.5% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.